Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $45.2 million.

  • Lineage Cell Therapeutics' Other Non-Current Liabilities changed N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $6.2 million for FY2024, which is N/A changed from last year.
  • Lineage Cell Therapeutics' Other Non-Current Liabilities amounted to $45.2 million in Q3 2025.
  • Lineage Cell Therapeutics' 5-year Other Non-Current Liabilities high stood at $45.2 million for Q3 2025, and its period low was $1000.0 during Q1 2023.
  • In the last 5 years, Lineage Cell Therapeutics' Other Non-Current Liabilities had a median value of $30000.0 in 2021 and averaged $5.9 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Other Non-Current Liabilities surged by 6923.08% in 2021, and later tumbled by 9880.38% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non-Current Liabilities (Quarter) stood at $30000.0 in 2021, then tumbled by 93.33% to $2000.0 in 2022, then crashed by 50.0% to $1000.0 in 2023, then surged by 616000.0% to $6.2 million in 2024, then soared by 633.18% to $45.2 million in 2025.
  • Its Other Non-Current Liabilities stands at $45.2 million for Q3 2025, versus $18.8 million for Q2 2025 and $6.1 million for Q1 2025.